ABVC

ABVC BioPharma (ABVC)

About ABVC BioPharma (ABVC)

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.

Details

Daily high
$2.08
Daily low
$2.00
Price at open
$2.06
52 Week High
$5.48
52 Week Low
$0.40
Market cap
50.1M
Dividend yield
0.00%
Volume
50,853
Avg. volume
70,712
P/E ratio
-9.23

ABVC BioPharma News

Details

Daily high
$2.08
Daily low
$2.00
Price at open
$2.06
52 Week High
$5.48
52 Week Low
$0.40
Market cap
50.1M
Dividend yield
0.00%
Volume
50,853
Avg. volume
70,712
P/E ratio
-9.23